CorMedix Inc (CRMD) - Total Assets
Based on the latest financial reports, CorMedix Inc (CRMD) holds total assets worth $826.14 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CorMedix Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CorMedix Inc - Total Assets Trend (2008–2025)
This chart illustrates how CorMedix Inc's total assets have evolved over time, based on quarterly financial data. Explore CRMD long-term investments to assets to see how much of total assets are deployed in long-term investments.
CorMedix Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
CorMedix Inc's total assets of $826.14 Million consist of 42.4% current assets and 57.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.7% |
| Accounts Receivable | $171.23 Million | 20.7% |
| Inventory | $29.72 Million | 3.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $379.07 Million | 45.9% |
| Goodwill | $30.00 Million | 3.6% |
Asset Composition Trend (2008–2025)
This chart illustrates how CorMedix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CorMedix Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CorMedix Inc's current assets represent 42.4% of total assets in 2025, a decrease from 85.5% in 2008.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 85.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 45.9% of total assets.
CorMedix Inc Competitors by Total Assets
Key competitors of CorMedix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
CorMedix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 3.39 | 27.24 |
| Quick Ratio | 1.84 | 3.16 | 27.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $176.20 Million | $80.74 Million | $80.01 Million |
CorMedix Inc - Advanced Valuation Insights
This section examines the relationship between CorMedix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.53 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | 595.1% |
| Total Assets | $826.14 Million |
| Market Capitalization | $600.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values CorMedix Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CorMedix Inc's assets grew by 595.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CorMedix Inc (2008–2025)
The table below shows the annual total assets of CorMedix Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $826.14 Million | +595.14% |
| 2024-12-31 | $118.85 Million | +44.83% |
| 2023-12-31 | $82.06 Million | +32.27% |
| 2022-12-31 | $62.04 Million | -10.02% |
| 2021-12-31 | $68.95 Million | +39.83% |
| 2020-12-31 | $49.31 Million | +67.28% |
| 2019-12-31 | $29.48 Million | +56.57% |
| 2018-12-31 | $18.83 Million | +39.93% |
| 2017-12-31 | $13.45 Million | -38.58% |
| 2016-12-31 | $21.91 Million | -40.96% |
| 2015-12-31 | $37.10 Million | +627.80% |
| 2014-12-31 | $5.10 Million | +71.77% |
| 2013-12-31 | $2.97 Million | +157.34% |
| 2012-12-31 | $1.15 Million | -54.88% |
| 2011-12-31 | $2.56 Million | -71.11% |
| 2010-12-31 | $8.85 Million | +297.54% |
| 2009-12-31 | $2.23 Million | +37.36% |
| 2008-12-31 | $1.62 Million | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more